• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
PharmaPoint: Epilepsy - Current and Future Players - Product Image

PharmaPoint: Epilepsy - Current and Future Players

  • ID: 2486854
  • February 2013
  • 58 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott
  • Dainippon Sumitomo Pharma
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE

PharmaPoint: Epilepsy - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Epilepsy - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Epilepsy Market. The report identifies and analyses the key companies shaping and driving the global Epilepsy market. The report provides insight into the competitive Epilepsy landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts.

Scope

- Investigation of current and future market competition for Epilepsy
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Epilepsy sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Epilepsy Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Epilepsy market landscape? Identify, understand and capitalize

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Dainippon Sumitomo Pharma
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers – Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 UCB
4.3.2 Eisai
4.3.3 Pfizer
4.3.4 GlaxoSmithKline
4.3.5 Novartis
4.3.6 Abbott
4.3.7 Dainippon Sumitomo Pharma
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Prevalent Epilepsy Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class Based on MOA
5.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Physicians and Specialists Included in this Study
5.6 Primary Research - Prescriber Survey
5.7 About the Authors
5.7.1 Authors
5.7.2 Global Head of Healthcare
5.8 About Us
5.9 Contact Us
5.10 Disclaimer

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Epilepsy, 2012–2022
Table 2: Global Epilepsy Market – Drivers and Barriers, 2012–2022
Table 3: Key Companies in the Epilepsy Market, 2012
Table 4: UCB’s Epilepsy Portfolio Assessment, 2012
Table 5: UCB SWOT Analysis, 2012
Table 6: Eisai’s Epilepsy Portfolio Assessment, 2012
Table 7: Eisai SWOT Analysis, 2012
Table 8: Pfizer’s Epilepsy Portfolio Assessment, 2012
Table 9: Pfizer SWOT Analysis, 2012
Table 10: GlaxoSmithKline’s Epilepsy Portfolio Assessment, 2012
Table 11: GlaxoSmithKline SWOT Analysis, 2012
Table 12: Novartis’ Epilepsy Portfolio Assessment, 2012
Table 13: Novartis SWOT Analysis, 2012
Table 14: Abbott’s Epilepsy Portfolio Assessment, 2012
Table 15: Abbott SWOT Analysis, 2012
Table 16: Dainippon Sumitomo’s Epilepsy Portfolio Assessment, 2012
Table 17: Dainippon Sumitomo SWOT Analysis, 2012
Table 18: Key Launch Dates
Table 19: Key Patent Expiries and Market Exclusivity Expiries-
Table 20: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales for Epilepsy by Region, 2012–2022
Figure 2: Company Portfolio Gap Analysis in Epilepsy, 2012–2022

Note: Product cover images may vary from those shown

UCB
Eisai
Pfizer
GlaxoSmithKline
Novartis
Abbott
Dainippon Sumitomo Pharma

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos